[ABEO] Abeona Therapeutics Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.8 Change: 0.15 (3.23%)
Ext. hours: Change: 0 (0%)

chart ABEO

Refresh chart

Strongest Trends Summary For ABEO

ABEO is in the medium-term down -47% in 2 months and down -70% below S&P in 4 months. In the long-term down -89% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-400 K Cash From Investing Activities-10 K Cash From Operating Activities-3.16 M Gross Profit
Net Profit-2 M Operating Profit-2 M Total Assets13.12 M Total Current Assets8.19 M
Total Current Liabilities1.24 M Total Debt Total Liabilities9.96 M Total Revenue260 K
Technical Data
High 52 week15.4 Low 52 week2.28 Last close2.29 Last change0.44%
RSI11.35 Average true range0.28 Beta0.56 Volume171.07 K
Simple moving average 20 days-26.72% Simple moving average 50 days-45.26% Simple moving average 200 days-65.83%
Performance Data
Performance Week-5.37% Performance Month-47.24% Performance Quart-70.18% Performance Half-64.93%
Performance Year-84.42% Performance Year-to-date-67.93% Volatility daily4.3% Volatility weekly9.61%
Volatility monthly19.7% Volatility yearly68.25% Relative Volume134.28% Average Volume688.89 K
New High New Low

News

2019-09-03 10:48:02 | Are Options Traders Betting on a Big Move in Abeona Therapeutics ABEO Stock?

2019-09-03 09:00:00 | Abeona Therapeutics Announces Strategic Review

2019-08-27 10:00:15 | Abeona Therapeutics Inc. NASDAQ:ABEO: What Does Its Beta Value Mean For Your Portfolio?

2019-08-12 21:11:44 | Edited Transcript of ABEO earnings conference call or presentation 12-Aug-19 2:00pm GMT

2019-08-12 18:23:21 | Abeona Therapeutics Inc ABEO Q2 2019 Earnings Call Transcript

2019-08-09 17:35:09 | Abeona Therapeutics ABEO Reports Q2 Loss, Misses Revenue Estimates

2019-08-09 16:15:00 | Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates

2019-08-01 10:33:02 | Analysts Estimate Abeona Therapeutics ABEO to Report a Decline in Earnings: What to Look Out for

2019-08-01 09:05:00 | The LD Micro Index Turns Four Years Old

2019-07-25 09:15:00 | Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA

2019-07-10 10:01:45 | How Many Abeona Therapeutics Inc. NASDAQ:ABEO Shares Did Insiders Buy, In The Last Year?

2019-06-26 08:00:00 | Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs

2019-06-23 16:42:31 | Here’s What Hedge Funds Think About Abeona Therapeutics Inc ABEO

2019-06-19 10:29:02 | Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

2019-06-18 08:29:00 | Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease

2019-05-21 08:00:00 | Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease

2019-05-15 02:11:50 | Edited Transcript of ABEO earnings conference call or presentation 14-May-19 2:00pm GMT

2019-05-14 20:23:12 | Abeona Therapeutics Inc ABEO Q1 2019 Earnings Call Transcript

2019-05-14 08:00:00 | Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B MPS IIIB

2019-05-10 16:27:20 | Abeona Therapeutics: 1Q Earnings Snapshot

2019-05-10 16:15:00 | Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

2019-05-08 08:30:00 | Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting

2019-05-07 16:15:00 | Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

2019-05-03 10:30:02 | Earnings Preview: Abeona Therapeutics ABEO Q1 Earnings Expected to Decline

2019-05-01 08:00:00 | Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting

2019-04-30 08:00:00 | Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting

2019-04-16 12:44:42 | Is Abeona Therapeutics's NASDAQ:ABEO 173% Share Price Increase Well Justified?

2019-04-15 14:41:32 | Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting

2019-04-04 08:25:00 | Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B MPS IIIB

2019-03-19 23:40:56 | Edited Transcript of ABEO earnings conference call or presentation 19-Mar-19 2:00pm GMT

2019-03-19 13:49:02 | Abeona Therapeutics Inc ABEO Q4 2018 Earnings Conference Call Transcript

2019-03-18 17:06:19 | Abeona Therapeutics: 4Q Earnings Snapshot

2019-03-18 16:45:00 | Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-22 11:25:47 | What Investors Should Know About Abeona Therapeutics Inc.’s NASDAQ:ABEO Financial Strength

2019-02-22 08:01:00 | Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference

2019-02-13 08:15:00 | New Research: Key Drivers of Growth for WPX Energy, ACADIA Pharmaceuticals, Lexicon Pharmaceuticals, MobileIron, Arrow Electronics, and Abeona Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

2019-02-11 16:05:00 | Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer

2019-02-01 07:30:00 | The Unknown Biotech Play that Could Deliver 400% Returns, or Much More

2019-01-31 08:00:00 | Abeona Therapeutics to Present New Supportive Data for Novel Gene Therapies at WORLDSymposium™

2019-01-08 13:00:00 | Abeona Therapeutics Strengthens Financial Leadership with New Executive Appointments

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-25 06:24:45 | How Should Investors Feel About Abeona Therapeutics Inc.’s NASDAQ:ABEO CEO Pay?

2018-12-13 03:03:08 | Is Abeona Therapeutics Inc ABEO A Good Stock To Buy?

2018-12-11 08:52:01 | Abeona Therapeutics ABEO in Focus: Stock Moves 5.5% Higher

2018-12-10 08:44:01 | Why Abeona Therapeutics ABEO Could Be Positioned for a Slump

2018-12-06 12:30:00 | Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day

2018-12-03 08:27:01 | Moving Average Crossover Alert: Abeona Therapeutics

2018-11-29 08:45:00 | Abeona Therapeutics to Host R&D Day on December 6, 2018

2018-11-27 08:00:00 | Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

2018-11-26 16:30:00 | Abeona Therapeutics Announces CEO Transition